Latest news with #AMPLITUDE
Medscape
2 days ago
- Health
- Medscape
ASCO 2025: Key Highlights in Prostate Cancer
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from abiraterone. He also discusses positive results from the AMPLITUDE trial, where adding niraparib to standard therapy improved radiographic progression-free survival, especially in patients with BRCA1 or BRCA2 mutations, reinforcing the need for comprehensive genomic testing. Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice-changing data are still forthcoming. He emphasizes the importance of leveraging technology and community collaboration to drive progress and improve outcomes in cancer care.
Yahoo
4 days ago
- Business
- Yahoo
ASCO 2025: Johnson & Johnson's Akeega set to be first PARP therapy for mCSPC
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the randomised, double-blind, placebo-controlled Phase III AMPLITUDE (NCT04497844) clinical trial were presented on 3 June. This trial evaluated the efficacy and safety of Johnson & Johnson's (J&J) Akeega, which includes Zejula (niraparib), a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor marketed by GSK for other indications, and Zytiga (abiraterone), a CYP17 inhibitor, plus the corticosteroid prednisone, in treating patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC), a condition in which the cancer has spread to other parts of the body but still responds to androgen deprivation therapy (ADT). Prostate cancer (PC) is the second most common cancer among men globally, following lung cancer, and patients with CSPC represent an area of unmet need in terms of available treatment options. According to GlobalData's Prostate Cancer: Epidemiology Forecast to 2033 report, the number of diagnosed five-year prevalent cases of PC in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 3,517,086 in 2025 to 4,236,251 by 2033. In the AMPLITUDE trial, a total of 696 patients with HRR gene-altered mCSPC were randomised 1:1 to experimental arm A (Akeega + prednisone; n=348) and comparator arm B (placebo + prednisone; n=348). The study achieved its primary endpoint of radiographic progression-free survival (rPFS). For patients with breast cancer (BRCA, or BRCA1 and BRCA2 ) gene mutations, a subset of HRR mutations, in arm A (n=191), median rPFS was not reached, compared to 26 months for arm B. This corresponded to a 48% reduction in the risk of progression or death (hazard ratio [HR] 0.52; 95% confidence interval [CI], 0.37 to 0.72; p<0.0001). Among patients with any HRR alteration in arm A, median rPFS was also not reached with the niraparib combination versus 29.5 months in arm B, reflecting a 37% reduction in risk (HR 0.63; 95% CI, 0.49 to 0.80; p=0.0001). The niraparib combination reduced the risk of symptomatic progression by 56% in BRCA-altered patients (HR 0.44; 95% CI, 0.29–0.68; p=0.0001) and by 50% in those with HRR alterations (HR 0.50; 95% CI, 0.36–0.69; p<0.0001), delaying symptom worsening and the need for additional interventions. The first interim analysis showed an early, but not statistically significant, trend toward improved overall survival (OS) favouring arm A, with a 25% reduction in the risk of death in patients with BRCA alterations (HR 0.75; 95% CI, 0.51–1.11; p=0.15) and a 21% reduction in those with HRR alterations (HR 0.79; 95% CI, 0.59–1.04; p=0.10). Follow-up is ongoing to reach data maturity. Grade 3 and 4 adverse events occurred more often in arm A than in arm B (75% versus 59%). This trial concludes that the combination of Akeega plus prednisone is a treatment option for patients with HRR-altered mCSPC, especially those with BRCA mutations. In 2023, the FDA approved Akeega in combination with prednisone for patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), based on the results of the MAGNITUDE trial. Currently, ADT and androgen receptor pathway inhibitors (ARPIs) remain the only treatment options for patients with mCSPC, with no PARP inhibitor therapies approved in this setting until now. The AMPLITUDE study results mark a significant milestone, positioning Johnson & Johnson's combination of a PARP inhibitor with ADT as the first targeted therapy for patients with BRCA-mutated mCSPC. However, the efficacy appears heterogeneous in the non-BRCA subgroup. A more detailed analysis is needed for this group, which makes up approximately 45% of the AMPLITUDE study population. Pfizer's Talzenna (talazoparib), in combination with Xtandi (enzalutamide), is currently being evaluated in the ongoing Phase III TALAPRO-3 trial for patients with DNA damage response-deficient mCSPC. AstraZeneca's next-generation, first-in-class PARP1 inhibitor, saruparib, is being assessed for efficacy and safety in HRR-mutated mCSPC patients in the Phase III EvoPAR-PR01 trial, in combination with either ADT or ARPI. First-generation PARP inhibitors are associated with higher toxicity, including bone marrow suppression and the risk of myelodysplastic syndrome. If saruparib demonstrates superior OS and a more favorable toxicity profile in the EvoPAR-PR01 trial, it may become the preferred option for clinicians over Akeega plus prednisone in HRR-mutated mCSPC. However, the estimated completion date for this trial is 2031, meaning that competition to Akeega could emerge in the later 2020s. According to GlobalData's analyst consensus forecast, global sales for Akeega are projected to reach $676 million by 2030, while Talzenna and saruparib are expected to reach $618 million and $628 million, respectively, in the same year. "ASCO 2025: Johnson & Johnson's Akeega set to be first PARP therapy for mCSPC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA. The results show a clinically meaningful and statistically significant improvement in both radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP), with an early trend toward improved overall survival (OS)—highlighting the potential of the combination in this patient population to delay both cancer progression and the worsening of symptoms.1 This marks the first Phase 3 data to show clinical improvement with a PARP-based combination in mCSPC. The findings are being presented as a late-breaking oral presentation (Abstract #LBA5006) at the 2025 American Society of Clinical Oncology Annual Meeting. The data have also been selected for Best of ASCO and included in the ASCO Press Program. "Approximately 25 percent of patients with mCSPC have HRR alterations, with about half being BRCA. These patients typically experience faster disease progression and poorer outcomes," said Gerhardt Attard*, M.D., Ph.D., FRCP, John Black Charitable Foundation Chair of Medical Oncology, University College London Cancer Institute, Research Department of Oncology and presenting author. "The AMPLITUDE trial is the first to show that combining a PARP inhibitor with an androgen receptor pathway inhibitor both delays disease progression and postpones the onset of symptoms in HRR-altered mCSPC, supporting this combination as a new treatment option for these patients." "Our aim with the AMPLITUDE study was to determine how long patients could live without their cancer worsening. What we found is that the combination of niraparib, abiraterone acetate, and prednisone is achieving just that, with the goal of offering patients precious quality time before the disease enters a more resistant phase," said Charles Drake, M.D., Ph.D., FAAP, Vice President, Prostate Cancer and Immunotherapy Disease Area Leader, at Johnson & Johnson Innovative Medicine. "This breakthrough highlights the need for early initiation of personalized treatment strategies for patients with mCSPC and HRR alterations, particularly BRCA, who typically face more aggressive disease." The Phase 3 AMPLITUDE study of 696 patients with mCSPC and HRR alterations met its primary endpoint of rPFS. Patients with BRCA alterations (n=191) showed the greatest benefit of treatment with the combination of niraparib plus AAP, as the median rPFS was not reached compared to 26 months in patients treated with the placebo plus AAP, reducing the risk of radiographic progression or death by 48 percent (hazard ratio [HR] 0.52, 95 percent confidence interval [CI], 0.37-0.72, p<0.0001). In patients with any HRR alteration treated with the niraparib combination, median rPFS was also not reached in comparison to 29.5 months in patients treated with the placebo plus AAP, with a reduction in risk of progression or death by 37 percent (HR 0.63, 95 percent CI, 0.49-0.80, p=0.0001).1 These results also showed that treatment with the niraparib combination reduced the risk of symptomatic progression by 56 percent in patients with BRCA alterations (HR 0.44, 95 percent CI, 0.29-0.68, p=0.0001) and 50 percent in patients with HRR alterations (HR 0.50, 95 percent CI, 0.36-0.69, p<0.0001), meaning that patients experienced a longer delay to worsening symptoms and requiring radiation, surgical intervention, or needing a new anti-cancer therapy. The first interim analysis showed an early trend toward improved overall survival (OS) favoring the niraparib/AAP combination with a reduction in risk of death of 25 percent (HR 0.75, 95 percent CI, 0.51-1.11, p=0.15) in patients with BRCA alterations and 21 percent in HRR alterations (HR 0.79, 95 percent CI, 0.59-1.04, p=0.10); follow-up is ongoing for maturity of the data.1 Grade 3/4 adverse events (AE) were more frequent with the niraparib combination compared to the placebo group (75 percent vs. 59 percent), with anemia and hypertension being the most common; however, treatment discontinuations due to AEs remained low (14.7 percent vs 10.3 percent). To date, the safety profile of niraparib plus abiraterone acetate and prednisone has been consistent with prior experiences.1 New data from the CAPTURE study (Abstract #5094), also being presented at the 2025 ASCO Annual Meeting with simultaneous publication in the Annals of Oncology, reinforce that the presence of HRR, specifically BRCA alterations, among patients with mCSPC are associated with significantly worse prognosis. Despite the availability of life-prolonging ARPIs, patients with HRR-altered mCSPC experience approximately 30 percent faster disease progression and shorter survival, while patients with BRCA-altered mCSPC experience approximately 50 percent faster disease progression and shorter survival—highlighting the importance of genetic testing to inform treatment decisions and the urgent need for novel targeted therapies to improve outcomes and delay progression.2 Johnson & Johnson has nearly 20 years of leadership in prostate cancer, treating more than 750,000 patients worldwide. With the AMPLITUDE study, Johnson & Johnson becomes the first to show that a PARP inhibitor combination can benefit patients with mCSPC.3 About AMPLITUDEAMPLITUDE (NCT04497844) is an ongoing, phase 3, randomized, double-blind, placebo-controlled, international study evaluating the efficacy and safety of niraparib and abiraterone acetate in a dual-action tablet (DAT) formulation with prednisone plus androgen deprivation therapy (ADT) compared to matching oral placebo/abiraterone acetate with prednisone plus ADT in patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The primary endpoint is radiographic progression-free survival (rPFS). About Metastatic Castration-Sensitive Prostate CancerMetastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that still responds to ADT and has spread to other parts of the body.4 About AKEEGA® (niraparib and abiraterone acetate)AKEEGA® is a combination, in the form of a dual-action tablet (DAT), of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor. AKEEGA® together with prednisone or prednisolone was approved in April 2023 by the European Medicines Agency, and in August 2023 by the U.S. FDA, for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Patients are selected for therapy based on an FDA-approved test for genetic alterations. Additional marketing authorization applications are under review across a number of countries globally. Additional ongoing studies include the Phase 3 AMPLITUDE study evaluating AKEEGA® with prednisone or prednisolone in a biomarker-selected patient population with metastatic castration-sensitive prostate cancer (mCSPC). In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline [GSK] in 2019) for exclusive rights to niraparib in prostate cancer. For more information visit AKEEGA® IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS The safety population described in the WARNINGS and PRECAUTIONS reflect exposure to AKEEGA® in combination with prednisone in BRCAm patients in Cohort 1 (N=113) of MAGNITUDE. Myelodysplastic Syndrome/Acute Myeloid LeukemiaAKEEGA® may cause myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). MDS/AML, including cases with fatal outcome, has been observed in patients treated with niraparib, a component of AKEEGA®. All patients treated with niraparib who developed secondary MDS/cancer-therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy. For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation. Discontinue AKEEGA® if MDS/AML is confirmed. MyelosuppressionAKEEGA® may cause myelosuppression (anemia, thrombocytopenia, or neutropenia). In MAGNITUDE Cohort 1, Grade 3-4 anemia, thrombocytopenia, and neutropenia were reported, respectively in 28%, 8%, and 7% of patients receiving AKEEGA®. Overall, 27% of patients required a red blood cell transfusion, including 11% who required multiple transfusions. Discontinuation due to anemia occurred in 3% of patients. Monitor complete blood counts weekly during the first month of AKEEGA® treatment, every two weeks for the next two months, monthly for the remainder of the first year and then every other month, and as clinically indicated. Do not start AKEEGA® until patients have adequately recovered from hematologic toxicity caused by previous therapy. If hematologic toxicities do not resolve within 28 days following interruption, discontinue AKEEGA® and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Hypokalemia, Fluid Retention, and Cardiovascular Adverse ReactionsAKEEGA® may cause hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. In post-marketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking abiraterone acetate, a component of AKEEGA®. Hypertension and hypertensive crisis have also been reported in patients treated with niraparib, a component of AKEEGA®. In MAGNITUDE Cohort 1, which used prednisone 10 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 2.7% of patients on the AKEEGA® arm and Grades 3-4 hypertension were observed in 14% of patients on the AKEEGA® arm. The safety of AKEEGA® in patients with New York Heart Association (NYHA) Class II to IV heart failure has not been established because these patients were excluded from MAGNITUDE. Monitor patients for hypertension, hypokalemia, and fluid retention at least weekly for the first two months, then once a month. Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia, or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. Control hypertension and correct hypokalemia before and during treatment with AKEEGA®. Discontinue AKEEGA® in patients who develop hypertensive crisis or other severe cardiovascular adverse reactions. HepatotoxicityAKEEGA® may cause hepatotoxicity. Hepatotoxicity in patients receiving abiraterone acetate, a component of AKEEGA®, has been reported in clinical trials. In post-marketing experience, there have been abiraterone acetate-associated severe hepatic toxicity, including fulminant hepatitis, acute liver failure, and deaths. In MAGNITUDE Cohort 1, Grade 3-4 ALT or AST increases (at least 5 x ULN) were reported in 1.8% of patients. The safety of AKEEGA® in patients with moderate or severe hepatic impairment has not been established as these patients were excluded from MAGNITUDE. Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment with AKEEGA®, every two weeks for the first three months of treatment and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop. Elevations of AST, ALT, or bilirubin from the patient's baseline should prompt more frequent monitoring and may require dosage modifications. Permanently discontinue AKEEGA® for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation, or in patients who develop ALT or AST ≥20 x ULN at any time after receiving AKEEGA®. Adrenocortical InsufficiencyAKEEGA® may cause adrenal insufficiency. Adrenocortical insufficiency has been reported in clinical trials in patients receiving abiraterone acetate, a component of AKEEGA®, in combination with prednisone, following interruption of daily steroids and/or with concurrent infection or stress. Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if patients are withdrawn from prednisone, have prednisone dose reductions, or experience unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with abiraterone acetate. If clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical insufficiency. Increased doses of corticosteroids may be indicated before, during, and after stressful situations. HypoglycemiaAKEEGA® may cause hypoglycemia in patients being treated with other medications for diabetes. Severe hypoglycemia has been reported when abiraterone acetate, a component of AKEEGA®, was administered to patients receiving medications containing thiazolidinediones (including pioglitazone) or repaglinide. Monitor blood glucose in patients with diabetes during and after discontinuation of treatment with AKEEGA®. Assess if antidiabetic drug dosage needs to be adjusted to minimize the risk of hypoglycemia. Increased Fractures and Mortality in Combination with Radium 223 DichlorideAKEEGA® with prednisone is not recommended for use in combination with Ra-223 dichloride outside of clinical trials. The clinical efficacy and safety of concurrent initiation of abiraterone acetate plus prednisone/prednisolone and radium Ra 223 dichloride was assessed in a randomized, placebo-controlled multicenter study (ERA-223 trial) in 806 patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer with bone metastases. The study was unblinded early based on an Independent Data Monitoring Committee recommendation. At the primary analysis, increased incidences of fractures (29% vs 11%) and deaths (39% vs 36%) have been observed in patients who received abiraterone acetate plus prednisone/prednisolone in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus prednisone. It is recommended that subsequent treatment with Ra-223 not be initiated for at least five days after the last administration of AKEEGA®, in combination with prednisone. Posterior Reversible Encephalopathy SyndromeAKEEGA® may cause Posterior Reversible Encephalopathy Syndrome (PRES). PRES has been observed in patients treated with niraparib as a single agent at higher than the recommended dose of niraparib included in AKEEGA®. Monitor all patients treated with AKEEGA® for signs and symptoms of PRES. If PRES is suspected, promptly discontinue AKEEGA® and administer appropriate treatment. The safety of reinitiating AKEEGA® in patients previously experiencing PRES is not known. Embryo-Fetal ToxicityThe safety and efficacy of AKEEGA® have not been established in females. Based on animal reproductive studies and mechanism of action, AKEEGA® can cause fetal harm and loss of pregnancy when administered to a pregnant female. Niraparib has the potential to cause teratogenicity and/or embryo-fetal death since niraparib is genotoxic and targets actively dividing cells in animals and patients (e.g., bone marrow). In animal reproduction studies, oral administration of abiraterone acetate to pregnant rats during organogenesis caused adverse developmental effects at maternal exposures approximately ≥ 0.03 times the human exposure (AUC) at the recommended dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of AKEEGA®. Females who are or may become pregnant should handle AKEEGA® with protection, e.g., gloves. Based on animal studies, AKEEGA® may impair fertility in males of reproductive potential. ADVERSE REACTIONSThe safety of AKEEGA® in patients with BRCAm mCRPC was evaluated in Cohort 1 of MAGNITUDE. The most common adverse reactions (≥10%), including laboratory abnormalities, are decreased hemoglobin, decreased lymphocytes, decreased white blood cells, musculoskeletal pain, fatigue, decreased platelets, increased alkaline phosphatase, constipation, hypertension, nausea, decreased neutrophils, increased creatinine, increased potassium, decreased potassium, increased AST, increased ALT, edema, dyspnea, decreased appetite, vomiting, dizziness, COVID-19, headache, abdominal pain, hemorrhage, urinary tract infection, cough, insomnia, increased bilirubin, weight decreased, arrhythmia, fall, and pyrexia. Serious adverse reactions reported in >2% of patients included COVID-19 (7%), anemia (4.4%), pneumonia (3.5%), and hemorrhage (3.5%). Fatal adverse reactions occurred in 9% of patients who received AKEEGA®, including COVID-19 (5%), cardiopulmonary arrest (1%), dyspnea (1%), pneumonia (1%), and septic shock (1%). DRUG INTERACTIONSEffect of Other Drugs on AKEEGA® Avoid coadministration with strong CYP3A4 inducers. Abiraterone is a substrate of CYP3A4. Strong CYP3A4 inducers may decrease abiraterone concentrations, which may reduce the effectiveness of abiraterone. Effects of AKEEGA® on Other Drugs Avoid coadministration unless otherwise recommended in the Prescribing Information for CYP2D6 substrates for which minimal changes in concentration may lead to serious toxicities. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug. Abiraterone is a CYP2D6 moderate inhibitor. AKEEGA® increases the concentration of CYP2D6 substrates, which may increase the risk of adverse reactions related to these substrates. Monitor patients for signs of toxicity related to a CYP2C8 substrate for which a minimal change in plasma concentration may lead to serious or life-threatening adverse reactions. Abiraterone is a CYP2C8 inhibitor. AKEEGA® increases the concentration of CYP2C8 substrates, which may increase the risk of adverse reactions related to these substrates. Please see the full Prescribing Information for AKEEGA®. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC, and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of AKEEGA® (niraparib/abiraterone). The reader is cautioned not to rely on these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. *Dr. Attard has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. Media contact: Oncology Media Relations Oncology_media_relations@ Investor contact:Lauren Johnson investor-relations@ medical inquiries:+1 800 526-7736 1 Attard, G., et al. (2025, May). Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer patients with alterations in homologous recombination repair genes. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.2 Olmos, D. (2025, May). Impact of somatic/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.3 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12. PMID: 30987939.4 American Society of Clinical Oncology. ASCO Answers: Prostate Cancer (2018). Accessed May 2025. View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Martechvibe
07-05-2025
- Business
- Martechvibe
Fuse Media Scales Advertising Impact Through AMPLITUDE
To help brands reach multicultural audiences, Fuse Media has launched AMPLITUDE, a new advertising platform. Staff Writer 47 minutes ago Fuse Media, a media company, announced the launch of AMPLITUDE, its new advertising platform designed to help brands with custom ad solutions that amplify their presence across today's dynamic media landscape. Fuse Media is known for its inclusive content and global multi-platform footprint across FAST, linear and SVOD with a combined audience of 52M+ unique viewers. Programming across Fuse's robust platform offerings targets culturally diverse young adults with purpose-driven stories across original series, documentaries, licensed content, and more. AMPLITUDE enables brands to unify efforts, streamline execution, and drive deeper impact with Fuse Media's unique audiences by harnessing cutting-edge ad technology, premium content, talent partnerships, and authentic storytelling. Brands of all business scales can tap into curated content strategies, high-impact cultural campaigns, deep data-driven performance insights, and interactive ad experiences fueled by partnerships with top ad tech partners, while Fuse Media's diverse talent network ensures meaningful connections with engaged, multicultural audiences. ALSO READ: Uniphore Acquires Hexagone 'Fuse Media has always led with culture—and our audiences are loyal, engaged, and growing. AMPLITUDE is the next evolution in advertising at Fuse Media, where cultural relevance, advanced technology, and authentic storytelling come together to help brands truly connect with today's cross-cultural consumers,' said Jim Keller, Chief Revenue Officer of Fuse Media. 'Whether you're a global advertiser or an emerging SMB, AMPLITUDE delivers more than just scale—it amplifies what matters most: connection, culture, and conversion.' AMPLITUDE's Planning tools, Integrations and Features; Reach through Culture Collective featuring a portfolio of 30+ premium CTV channels that expands upon Fuse Media's O&O CTV channels through strategic partnerships with Lionsgate, Tastemade, Trusted Media Brands, and Hartbeat to bring massive scale to advertisers. Audience and Contextual Targeting Tools through Freewheel's Audience Manager, providing real-time audience sizing, faster forecasting, and smarter ad delivery that benefits everyone in the media value chain. Programmatic automation via PMP (Private Marketplace), PG (Programmatic Guaranteed), Agency Deals and First Look Deals reaching the target audience with Fuse Media's CTV scale and pricing. Therefore, connecting brands through all major DSPs (Demand-Side Platforms) and SSPs (Supply-Side Platforms). Empowering Brand Partners with Advertiser Insights via Fuse Media's Business Intelligence, including category trends, brand lift studies, audience surveys, and performance analytics—driving data-informed strategies and maximising campaign impact. Curated Solutions through Content Strategy & Ignition Studios for brands to strategically reach audiences through demo-based, seasonal and flexible thematic programming as well as custom-crafted, branded content rooted in audience affinities and inclusive storytelling. High-Impact Custom Executions and Unique Culture Amplifiers activating branded content based on audience affinities and authentic storytelling, as well as exclusive key cultural editorial franchises including Buy Small, Future History and ProfitHub. Deepened Impact Evolving the Consumer Journey Through Ad Experiences in Partnership with Brightline, GumGum, Amagi & TripleLift, providing interactive ads that drive engagement with customised In-Stream and In-Content ad executions as well as graphic overlays. Democratised Access to Premium Video for Advertisers of All Sizes via Universal Ads, enabling SMB (small/medium-sized businesses) brands to seamlessly make and buy commercials across the Fuse Media video ecosystem, reaching new qualified audiences at scale. Diverse Audiences, Authentic Voices and Loyal Fans Through Fuse Media's Talent Network, leveraging Fuse Media's talent pool of 100+ creators and hosts to authentically reach diverse audiences. ALSO READ: Mundial Media Raises $1.5 Million The Martechvibe team works with a staff of in-house writers and industry experts. View More advertisingAmplitudeFuse MediaMediaMulticultural Audiences Locala's omnichannel advertising platform leverages granular insights and cutting-edge AI to help marketers plan, activate, and measure campaigns that are personalised to the local consumer. It specialises in transforming complex mobility and consumer data into actionable audience insights, fueling advanced media strategies. VISIT WEBSITE Blue Prism is a global software provider, offering ROM 2, an intelligent automation implementation methodology that empowers teams to scale their digital workflow. One of its use cases is sales and marketing solutions, which is powered by artificial intelligence (AI) and machine learning (ML) algorithms. VISIT WEBSITE Pega is a combined business process management and robotic process automation (RPA) platform that comes with workforce analytics features. It offers a wide variety of tools such as Pega Email Bot to automate repetitive tasks with personalised customer replies at scale. VISIT WEBSITE EdgeVerve, a subsidiary of India-based IT company Infosys Technologies, offers RPA software for major enterprise companies. Its AssistEdge Robotic Process Automation provides machine learning and AI tools called Infosys Nia. Its AssistEdge RPA enables global marketing and distribution companies to automate 970+ manual tasks at scale. VISIT WEBSITE Clevertap is a comprehensive platform that allows global marketers to get unified customer data analytics and omnichannel engagement in one place. VISIT WEBSITE UseResponse is a fully customisable customer support and feedback software, helping companies to better understand the needs of their customers. It provides the capabilities of multichannel ticketing, live chat with messengers aggregator, chatbot, feedback community portal, and knowledge base. VISIT WEBSITE Survicate is a drag-and-drop, multichannel survey builder, helping brands effortlessly collect and analyse customer feedback. It offers 23+ one-click, native integrations, enabling advertisers and marketers to create follow-up campaigns based on real-time customer feedback. VISIT WEBSITE SAP Sales Cloud comes with end-to-end solutions and offers AI-fueled insights for understanding customers' preferences. It helps build customer profiles at scale. It also empowers users to automatically manage contact information, which streamlines clients' journeys. VISIT WEBSITE Freshsales by Freshworks is an AI-powered software that streamlines the sales cycle by automating mundane tasks and personalising customer engagement. It generates quality leads and nurtures relationships by understanding visitor intent in real-time. VISIT WEBSITE Developed for midsize enterprises and large organisations, Creatio offers end-to-end CRM software solutions, allowing users to manage sales, marketing, and services all in one place. For marketing professionals, it provides Marketing Creatio, an omnichannel marketing platform to orchestrate customer journeys and accelerate lead-to-revenue. VISIT WEBSITE Salesforce is a global technology provider, offering low code/no-code, AI-powered capabilities. Marketers and advertisers can harness its technologies for multiple use cases like B2B strategies, cross-channel personalisation, real-time analytics, and more. VISIT WEBSITE SAS offers embedded CDP capabilities, letting marketers unify customer data, understand digital activity and enable analytically driven, real-time activation. It comes with data activation facility that enables marketers to pull only the data they want, further reducing data migration costs. VISIT WEBSITE Blueshift is a scalable CDP platform that offers AI-driven capabilities for clubbing real-time events with related data from various sources. It streamlines these insights into unified customer profiles, enabling marketers to automatically personalise their targeting goals. VISIT WEBSITE Wotnot is a genAI-powered , no-code chatbot platform, helping the sales and marketing team to engage with visitors on their website via personalised conversations, catering to their lead-generation goals. It offers platform-based solutions, such as AI Studio, a GPT chatbot builder, and an analytics dashboard. VISIT WEBSITE Aisera is a generative AI platform provider that offers AI Copilot, AiseraGPT, and AiseraLLM for various domains. With Aisera, enterprises can accelerate the development of their LLMs or purchase ready-to-use generative AI solutions with pre-trained LLMs using customer data to reduce hallucinations. VISIT WEBSITE Deliotte offers Ncyte, an all-in-one analytics solution. Utilising patented algorithms, proprietary data models and predictive analytics, Ncyte delivers actionable insights for various marketing functions. With Nycte, data and marketing teams can pre-define events such as attributed campaign performance to evaluate their efforts with live notifications. VISIT WEBSITE CleverTap is a customer engagement and retention platform that offers the functionality to integrate app analytics and marketing. Powered by TesseractDB, a purpose-built database for engagement & retention, it combines the features of audience analytics, omnichannel engagement, and product A/B testing for marketing functions. VISIT WEBSITE Oracle Advertising and Customer Experience (CX), lets advertisers personalise their campaigns. Its flagship product, Oracle Moat, a comprehensive analytics and measurement platform, provides a suite of solutions across marketing and ad intelligence. Moat helps reach prospective customers, capture consumer attention, and measure the outcomes to unlock business potential. VISIT WEBSITE Meta Ads is a social media advertising platform leveraging the user base from Facebook, Instagram and Whatsapp to deliver personalised ads at scale. It offers Meta Business Suite and Meta Business Manager for managing and tracking ad performance. Utilising its AI-powered tools, advertisers can partially or fully automate with complete control over their ads. VISIT WEBSITE WebEngage is an end-to-end customer data platform, helping brands to strategise their customer engagement and retention functions. It supports third-party integration for use cases including customer segmentation, omnichannel engagement, and survey & feedback. VISIT WEBSITE ServiceNow features Robotic Process Automation Hub (RPA Hub), a scalable genAI-powered platform for orchestrating and managing a robotic workforce to execute various business processes. Its workflow automation enables tasks like lead management and campaign execution and supports integration with popular marketing tools to streamline processes. VISIT WEBSITE Tealium is a comprehesive customer data platform helping brands orchestrate and manage their data activation from a marketing standpoint. Its AudienceStream CDP functionality enables marketers to create custom campaigns via 1300+ integration options for several use cases. VISIT WEBSITE Qualaroo is a saas-based online survey creator offering Qualaroo Nudge, a proprietary technology for uploading custom properties for airtight targeting. It enables marketers to 'nudge' when user clicks on a page element, helping them to target visitors on their real-time activity. VISIT WEBSITE Zendesk is a Danish-American company that offers software-as-a-service products with the capabilities of omnichannel integrations. Its omnichannel messaging platform enables sales and marketing teams to easily track and consolidate customer tickets from various sources, ensuring enhanced customer experiences. VISIT WEBSITE WebEngage is an all-in-one marketing platform that integrates omnichannel engagement with live analytics features. It offers AI/ML-driven product recommendations engine that enables marketers to boost conversion for all channels, including the web and mobile apps. VISIT WEBSITE Sprinklr is a comprehensive enterprise software company offering omnichannel support capabilities for all customer-focused marketing functions. It provides no-code, easy-to-build API integrations to access real-time customer data from multiple sources — such as CRM, CDP and ecommerce platforms. VISIT WEBSITE SAP provides omnichannel marketing capabilities through its flagship product: SAP Emarsys. By accessing its purpose-built reports, teams can determine the effectiveness of their marketing campaigns, segments, and channels in achieving sales goals. Its B2B account engagement features let brands deliver predictable and personalised marketing-led B2B insights at scale. VISIT WEBSITE MoEngage is a global AI-driven marketing platform that enables brands to orchestrate omnichannel campaigns from a single intuitive interface. Utilising MoEngage's User Path Analysis capabilities, marketing teams can target customers across 10+ channels, depending on their purchase behaviour. VISIT WEBSITE Intuit Mailchimp is an AI-powered omnichannel platform that offers email and marketing automation functions. With its customised pre-built audience segments, marketers can scale their campaigns based on individual contacts' demographic information and shopping behaviour. VISIT WEBSITE Hubspot is a cloud-based, scalable customer platform that offers various marketing automation solutions with omnichannel support capabilities. It enables marketers to create omnichannel campaigns to connect and interact with customers across multiple channels in real-time. VISIT WEBSITE Bloomreach is an all-inclusive marketing automation platform that comes with omnichannel orchestration supports for various use cases, such as marketing campaign personalisation, and headless CMS commerce platform experience. VISIT WEBSITE Agillic specialises in offering global brands a comprehensive Omnichannel Marketing Automation Platform that enables them to create personalised marketing campaigns. Its multichannel marketing capabilities support multiple integrations, such as Playable and Sleeknote for lead generation, Zapier for automating routine processes, among others. VISIT WEBSITE Adobe Experience Cloud features Adobe Campaign, enabling marketers to synchronise their customer data from various channels for omnichannel marketing. By leveraging its omnichannel integration with Adobe Journey Optimiser, brands can build multi-step journeys, campaigns, and personalised real-time moments that follow their customers across channels. VISIT WEBSITE ActiveCampaign is an intelligent multichannel marketing automation platform that enables marketers to seamlessly connect campaigns across the channels that matter most to them. It helps enterprises streamline personalised marketing, transactional emails, and one-to-one CRM interactions throughout the customer lifecycle. VISIT WEBSITE UiPath offers a comprehensive AI-powered robotic automation platform, enabling marketers to streamline recurring functions, such as lead automation and customer engagement. Utilising its capabilities, marketers can personalise and automate customer interactions, depending on their needs and preferences. VISIT WEBSITE SAP is a composable marketing automation technology provider, offering SAP Intelligent RPA solutions to automate repetitive, rules-based business processes, including marketing and sales. Using its tech stack, marketers can automatically extract product data from manufacturers' websites, update online inventory and import website and email sales. VISIT WEBSITE Microsoft offers Power Automate, a low-code and AI-powered RPA software that helps marketers streamline tasks like lead management, email campaigns, social media management, data analysis, content publishing, and customer feedback. Leveraging its capabilities, businesses can automate repetitive tasks, such as lead capture and email marketing workflows. VISIT WEBSITE IBM offers AI-powered Robotic Process Automation capabilities for CRM and marketing functions. It enables users to automate workflows with integrated OCR and intelligent chatbots, distribute work across multiple bots without human interventions and manage emails via low-code authoring tools. VISIT WEBSITE Hyland offers an AI-powered comprehensive robotic automation software suite, enabling marketers' teams to automate their campaigns. Its Natural Language Processing (NLP) technology allows businesses to automate repetitive marketing functions, such as execution of targeted and personalised strategies in near real-time. VISIT WEBSITE Datamatics is an intelligent automation platform, offering TruBot RPA designer, a low-code bot design tool for marketing teams to create customised bots quickly. It provides 500 pre-built components, enabling low-code design and rapid deployment capabilities with drag-and-drop options. VISIT WEBSITE Automation Anywhere offers Automation Success Platform powered by Vertex AI, enabling enterprises to develop a cloud-based digital workforce at scale. Leveraging its bots, ML, and AI technologies, marketers can automate their marketing and sales processes. One of its popular offerings is Automation Co-Pilot, a genAI-powered assistant that empowers businesses to create and summarise content. VISIT WEBSITE Appian is a global technology provider, delivering end-to-end process automation with RPA, AI, IDP and API integrations. Utilising the readily available APIs of this low-code platform, teams can create a series of connected digital business applications including customer management and marketing. VISIT WEBSITE Powered by Zoho Corporation, Zoho Analytics enables marketers to track all critical metrics in a single platform to enhance marketing outcomes. The company offers 75 pre-built data visualisation reports and dashboards on marketing performance for collaborative analysis. With its AI-powered assistant, marketers can generate automated insights, predict future trends, and configure smart alerts. VISIT WEBSITE Semrush is an online visibility management and content marketing SaaS platform, offering marketing analytics tools to global businesses. Its open-source analytical tools include Market Explorer and Traffic Analytics for understanding market trends and website traffic respectively. VISIT WEBSITE Nielsen is a global audience insights, data and analytics solution provider, helping marketers measure what people listen to and watch. It offers a comprehensive, AI-powered Nielsen Marketing Cloud platform with sub-products such as Audience Segments, Scarborough, and Advanced Audiences to understand audiences for different targeting initiatives. VISIT WEBSITE MoEngage is a full-stack marketing automation platform, offering consumer insights and analytics solutions for marketers to understand customer LTV. With MoEngage Analytics, they can measure user engagement, spot behavioural patterns, and act on retention to prevent app uninstalls. VISIT WEBSITE Microsoft Clarity is a behavioural analysis tool that helps marketers understand user interaction with their website. It supports features like Session recordings, Heatmaps, and ML insights in real time. Processing more than a petabyte of data from over 100 million users per month, Clarity accommodates limitless traffic for various marketing measurements at scale. VISIT WEBSITE Powered by AI-led insights, Merkle offers scalable marketing analytics and CX technology solutions, helping brands to optimise their campaigns. Some of its flagship solutions are Measurement & Media analytics, Consumer & Experience insights, and Product & Market intelligence. VISIT WEBSITE Hubspot offers marketing analytics and dashboard software, enabling businesses to make data-backed decisions for use cases, such as revenue generation, site analytics and detailed reporting. Leveraging the capabilities of its multi-touch revenue attribution model, marketers can monitor real-time website traffic via unique tracking codes. VISIT WEBSITE Google Analytics is an open-source analytics tool by Google, enabling marketing teams within organisations to better understand their customers via valuable insights. Consequently, businesses can use those insights to take action, such as website improvement and tailored audience list creation. VISIT WEBSITE Adverity is an integrated data analytics platform, enabling marketers to automate their customer's data integration and visualisation functions. It offers 600+ pre-built data connectors to popular marketing platforms, social media networks, SEO tools, and marketing automation solutions. The platform also provides pre-build dashboards to generate tailored reports. VISIT WEBSITE Adobe Experience Cloud offers Adobe Analytics and Adobe Target within its analytics tools solutions, enabling marketers to execute in-depth analysis of their customer data. Adobe Analytics allows the sales and marketing teams to mix, match, and analyse data from any digital point in the customer journey. VISIT WEBSITE Ahrefs features a suite of analytics tools under its Ahref Enterprise offering. It offers API and Looker Studio connectors, enabling marketing teams to elevate their SEO strategy with enterprise-grade and insights. Some of the criteria for its API endpoints include Backlinks, Organic & Paid Traffic, SERPs, Website health score and more. VISIT WEBSITE StackAdapt is a multi-channel programmatic advertising platform, enabling digital marketers to customise their strategy. It offers open and flexible DSP (Digital Signal Processing) capabilities for executing tailored ad campaigns. Furthermore, its ad previewer lets marketing teams preview video, display and native ads on desktop or mobile across 500+ publishers, covering 23 verticals. VISIT WEBSITE Rakuten is a global affiliate ad technology company, enabling advertisers to optimise their marketing strategies with data-driven insights. It offers AI-powered forecasting and benchmarking capabilities and dynamic multi-touch commissioning tools, allowing advertisers to customise their campaigns. It also supports first-party data collection integrations for both B2B and B2C marketers. VISIT WEBSITE Nielsen offers Nielsen Ad Intel, a cross-platform advertising intelligence platform with actionable insights to identify prospects, analyse brand strategies and learn from past advertising campaigns. It offers various advertising intelligence features such as ad spend monitoring, competitive benchmarking, global competitive insights and expert data harmonisation. VISIT WEBSITE Magnite is an independent sell-side advertising technology provider, enabling publishers to monetise their content across all screens and formats. It offers Magnite Streaming, a singular supply-side platform that merges technology from the Magnite CTV and SpotX platforms. Utilising this functionality, marketers can identify their potential audiences to restructure their targeting strategies. VISIT WEBSITE IBM offers a comprehensive suite of Watson Advertising to agencies and marketers. With Watson Advertising's AI-powered assistant, advertisers can customise their advertisements, based on real-time ad results. It also supports functionalities of cookieless advertising, ad fraud management and brand safety measurements. VISIT WEBSITE Google features a comprehensive list of AI-powered Ad tools under its Google Ads offering. Some of its popular tools include Keywords Planner, Ads Editor, Reach Planner, Ads Mobile App, Insights Finder, Ads API, and Recommendations Page. Additionally, it offers Google AdMob to help businesses plan their in-app revenue generation strategy. VISIT WEBSITE Criteo is an all-in-one connected commerce media platform, enabling marketers and agencies to scale their digital and physical assets. Leveraging the capabilities of its AI-powered technology, brands can develop strategies for intent-based product recommendations, multi-prolonged accessibility, contextual advertising, and more. VISIT WEBSITE Basis Tecnologies (formerly known as Centro), is a programmatic advertising platform, offering ad management tools for search, social and site direct via a single interface. Its flagship products are Basis Assistant and Basis Automate+. Basis Assistant is a Chrome extension, connecting 20+ platforms and tools, and Basis Automate+ is a digital advertising automation tool for simplifying campaign process. VISIT WEBSITE AppsFlyer is a mobile attribution company, helping mobile advertisers to identify their ad network. It offers a measurement suite, giving app marketers full visibility into their customer journeys while preserving their privacy. Utilising its AI-powered Creative Optimisation platform, marketers can formulate their creative strategy. VISIT WEBSITE Adtriba is a cross-channel digital marketing management platform based on data-driven attribution modelling. Its solutions include Adtriba Triangulation, enabling advertisers to witness the integration of diverse measurement methods, such as Marketing Mix Modelling (MMM), Multi-Touch Attribution (MTA) and Incrementality Testing. VISIT WEBSITE Adobe Experience Cloud offers connected advertising solutions with its natively integrated Adobe Advertising platform. Its consultancy-based reporting options come with AI-powered optimisation features, helping advertisers analyse their ad performance via 200+ measurement metrics. Utilising its connected TV (CTV) and search, social, and commerce tools, marketers can optimise their customer acquisition strategy. VISIT WEBSITE specialises in Conversational AI, generating autonomous conversations that appear human-like. These conversations form the foundation of brand engagement. Their AI-powered, no-code Dynamic Automation Platform manages around two billion conversations from a multitude of channels in numerous languages. VISIT WEBSITE Sprinklr offers a comprehensive suite of 250+ AI-intent bot templates for various industry verticals to accelerate bot development. Its specialised AI and compliant rule engine enables marketers to modify and automate their promotional campaigns for better engagement via suggestion-based personalised bots. VISIT WEBSITE Meta's new class of generative AI features and creative tools allow users to create and share custom stickers or update the visual style of their photos with a simple text prompt. They can also chat with 28 different AIs and get unique perspectives on topics like travel, games and food. VISIT WEBSITE is a UI-based platform that allows marketers to create a chatbot quickly and deploy it easily on multiple channels. Leveraging the capabilities of its conversational builder, enterprises can build the Dialogflow using dialogue messages. Some of its popular offerings include XO: Experience Optimisation and GALE(Beta). VISIT WEBSITE IBM watsonx Assistant is an interactive virtual agent that utilises natural language and AI, enabling users to set it up on their app and website. It offers fast and accurate responses to customers, enhancing their overall experience and satisfaction with its adaptive learning capabilities. VISIT WEBSITE Haptik helps enterprises manage their customer lifecycle with generative AI-powered conversational solutions to boost marketing and sales. It offers Contakt and Interakt to enhance overall CX, where Interakt enables marketers to send hyper-targeted and personalised campaigns to drive customers to take action on WhatsApp. VISIT WEBSITE Dialogflow is an all-in-one platform for developing chatbots, voice bots, and virtual agents using natural language understanding and Google AI. It helps marketing teams create conversational agents that can handle common customer requests and issues, such as FAQs, and order status at scale. VISIT WEBSITE Dialpad is a fully integrated unified conversation intelligence platform that utilises ongoing ML(Machine Learning) algorithms and does not require coding to configure a chatbot. It offers real-time insights and tips, helping marketing teams customise their approach for every customer. VISIT WEBSITE is a low code-no code, enterprise-grade generative AI platform offering readily available LLMs for CX transformations. Its omnichannel reporting and analytics suite for marketing enables organisations to streamline their customer journeys. VISIT WEBSITE is a global conversational AI technology provider optimised for operational efficiency at scale. It offers self-learning AI capabilities that emphasise Natural Language Understanding (NLU) along with intent suggestions. VISIT WEBSITE Avaamo is an all-in-one conversational AI platform for enterprises offering a suite of industry-specific skills developed to automate and resolve common use cases. It offers Outreach, which enables marketers to educate and engage with customers across existing touchpoints through proactive and personalised communication. VISIT WEBSITE Amazon Lex offers fully managed conversational AI interfaces with advanced natural language models to design, build, test, and deploy conversational interfaces in applications. It enables sales and marketing teams to automate user tasks in their applications like the CRM and across any digital channel. VISIT WEBSITE Zendesk is an AI-powered customer feedback software provider, offering customer satisfaction (CSAT) software to businesses across multiple industries. Its marketplace offers 1600+ apps and integrations, enabling marketers to create a complete customer feedback system. VISIT WEBSITE UserVoice provides product feedback management software for SaaS businesses. Its UserVoice Validation tool delivers actionable user insights to inform roadmap strategy. From testing ideas to ensuring satisfaction with released features, it helps research and marketing teams gather quick user feedback throughout the entire product lifecycle. VISIT WEBSITE Twilio provides integrated Mindful Feedback functionality within its Flex offering, enabling marketers to automatically take action based on real-time customer feedback. It automatically collects customer feedback after Flex interactions by capturing feedback over post-call voice IVR, outbound voice IVR, conversational SMS, Web SMS, email, and web surveys. VISIT WEBSITE Trustpilot offers ML and AI-powered feedback management tools, helping marketers build trust and loyalty through customer reviews. Its AI-driven Review Insights tool enables marketers to identify growth areas from negative feedback, whereas its Image Generator tool lets them enhance social media engagement. VISIT WEBSITE Survey Monkey is a global online survey and forms tech stack provider, offering AI-fueled market research solutions to businesses. Its enterprise feedback management program provides 250+ templates with the capabilities of customisation, allowing organisations to build tailored survey forms. VISIT WEBSITE Sprinklr is a unified customer experience platform (CXM), offering AI-powered feedback management capabilities with its flagship product: Sprinklr Surveys. It integrates solicited customer feedback with unified-CXM data, enabling brands to derive meaningful, actionable insights. Utilising its genAI-powered survey builder, marketers can create conversational surveys to streamline their NPS strategies. VISIT WEBSITE Salesforce is a comprehensive customer-oriented technology provider offering a feedback management suite. Salesforce's survey responses help marketers create personalised surveys based on their existing customers' data. Some of the supported applications of its feedback management platform are genAI-powered survey form development and sentiment-insights-based survey collections. VISIT WEBSITE QuestionPro is an online feedback software provider, offering ready-made survey templates to businesses across 40+ countries. Leveraging the capabilities of its customer satisfaction templates, advertisers and marketers can create and gather tailored questions. VISIT WEBSITE Qualtrics is an all-in-one customer experience solution provider, offering website & app feedback tools for organisations to collect customer feedback efficiently. Its digital experience analytics capabilities combined with DXA integrations, bring together verbal and behavioural data for in-depth analysis of user feedback. VISIT WEBSITE HubSpot is a one-stop marketing platform, providing customer feedback software under its Service Hub offerings. Its pre-built APIs include net promote score (NPS), customer effort score (CES), and customer satisfaction (CSAT) surveys, allowing marketers to strengthen their customer loyalty strategy. VISIT WEBSITE Medallia is a comprehensive platform, enabling marketers to capture feedback from all customer touch points. Some of its popular feedback management software capabilities include Sense360 for analysing consumer spending, Medallia Video to automatically extract meaningful insights from customer's feedbacks and Agile Research for creating branded surveys in real-time. VISIT WEBSITE Zeotap lets brands integrate, unify, segment and orchestrate customer data, fostering a cookieless future. It offers a 'Non-Customer Entity Data' feature that helps marketers to integrate both customer and non-customer entity data. VISIT WEBSITE Twilio provides, Twilio Segment, an AI-powered CDP, enabling marketers to streamline their personalised customer engagement journeys. It brings together clean, consented customer data for real-time insights with 450+ pre-built connectors. VISIT WEBSITE Syntasa provides data-ready CDP capabilities, equipping marketers with essential tools to prepare their customer data. It offers real-time sentiment analytics capabilities, helping enterprises derive behavioural insights from unified user profiles to foster hyper-personalised experiences. VISIT WEBSITE SAP is a company-wide customer data management platform, helping marketers improve engagement, conversion, and retention. It offers a genAI-powered data model, enabling enterprises to unify their B2B and B2C customers' profiles to reach their personalisation goals. VISIT WEBSITE Oracle is a global database management company, providing CDP solutions, under its flagship product: Oracle Unity. Its AI-powered models enable marketers to create hyper-personsalised campaigns with predictive insights by streamlining real-time customer data from heterogeneous sources. VISIT WEBSITE Growthloop is a composable CDP platform, allowing marketing and sales team to action their data at scale. It offers GrowthLoop Audience Builder, enabling marketers to initiate their lead generation functions. VISIT WEBSITE Adobe Experience Cloud offers a real-time CDP, letting users create high-value audience segments for B2C and B2B use cases across their marketing funnel. It follows a cookieless marketing approach to automatically unify customer data across various online and offline channels in real-time. VISIT WEBSITE ActionIQ is a composable CDP platform that offers audience segmentation, acquisition marketing, and Customer 360 capabilities. It integrates analytical tools, enabling marketers to collect and analyse their first-party customer data at scale. VISIT WEBSITE Zoho CRM leverages automation and comprehensive analytics to empower any sales team, fostering stronger customer loyalty. Ideal for both small businesses and enterprises, this software enables enhanced productivity and tailored solutions through predictive intelligence. VISIT WEBSITE Zendesk offers Zendesk Sell, an easy-to-deploy CRM platform that is simple to deploy and navigate, catering to businesses of any scale. Its mobile-friendly Sell app has the functionalities of geolocation, helping sales and marketing teams. Offering an all-in-one CRM platform, organisations can implement use cases like prospecting, engagement, lead generation and communication capabilities. VISIT WEBSITE SugarCRM is a global CRM software provider, helping marketing, sales, and service teams improve efficiency through automation, data, and intelligence in near real-time. It offers Sugar Market, an all-in-one marketing automation platform that helps marketers to automate their campaign with higher ROI. VISIT WEBSITE Salesforce is a one-stop sales and support CRM software that regularly updates customer records, tracks emails and calls, and creates organised support processes for quicker customer responses. Its simple and scalable infrastructure is ideal for businesses of all sizes. VISIT WEBSITE Pipedrive stands out with its emphasis on automation, tailorability, and seamless integration. Purposefully built to enhance the efficiency and productivity of sales professionals, this CRM solution has an intuitive setup and robust capabilities. It facilitates lead generation, comprehensive sales analytics, and seamless business expansion. VISIT WEBSITE Oracle NetSuite CRM, a component of Oracle's business software suite, is for all midsize and booming businesses that want a comprehensive, integrated CRM solution with ERP capabilities. Using it, customers and partners can directly interact with the platform, freeing the additional work load for their sales team. VISIT WEBSITE Microsoft Dynamics 365 Sales represents a robust cloud-based CRM solution brimming with features such as pipeline assessment, relationship analytics, and conversational intelligence. It utilises AI-powered insights to provide actionable intelligence via predictive analytics, lead scoring and sentiment analysis. VISIT WEBSITE Less Annoying is a CRM software that utilises a straightforward search feature within its contact management system, making it easy to track contacts. It is ideal for small-sized businesses and offers a highly intuitive and user-friendly interface. VISIT WEBSITE Insightly offers CRM software solutions for enterprises looking to understand their audience data across various marketing functions. It integrates seamlessly with third-party apps, streamlining workflow automation, including bulk emailing and report generation. VISIT WEBSITE HubSpot's sleek dashboard with consolidated CRM tools simplify complex customer data, further transforming it into meaningful insights. Complementing typical CRM functionalities, HubSpot provides tailored options, including conversation intelligence and email monitoring. VISIT WEBSITE Apptivo delivers adaptable and web-based CRM solutions, enabling marketing and sales teams to streamline all customer service requirements across various devices and browsers. Despite its focused feature set, it encompasses over 65 interconnected applications alongside a robust sales pipeline management tool, ensuring efficient tracking of potential leads without any downtime. VISIT WEBSITE Sitecore offers composable cloud solutions with its flagship products, Sitecore Experience Platform(XP) and Sitecore Experience Manager (XM). They help marketers to overcome scalability challenges. Some of its features include intuitive visual editing, headless delivery, marketing automation, scalable personalisation, data and machine learning capabilities. VISIT WEBSITE Salesforce Experience Cloud is a platform that helps enterprises link clients, partners, and employees to securely exchange information and documents. Built on its Customer 360 platform, Salesforce's DXP ensures seamless integration with any solution in the Salesforce ecosystem. VISIT WEBSITE Oracle Cloud offers a comprehensive suite of platform-based marketing automation solutions for personalised B2B and B2C automation campaigns. Some of its featured products are Eloqua Marketing Automation, CrowdTwist Loyalty and Engagement, and Unity Customer Data Platform. VISIT WEBSITE Optimizely is a digital experience platform (DXP) provider that offers Optimizely One, an easy-to-use and fully integrated suite. It provides a single, unified workflow with thoughtfully embedded AI and machine-learning algorithms, accelerating work across the entire marketing lifecycle. VISIT WEBSITE OpenText offers a cloud-native, scalable platform for enterprises to streamline their marketing functions. It provides fully composable content management, digital asset management, creative workflows, personalisation, targeting and customer data technologies in one place, ensuring a holistic approach to B2B, B2E and B2C experiences. VISIT WEBSITE Neptune DXP is a PaaS(Platform-as-a-Service) provider, helping marketing teams build custom apps based on modular, reusable application building blocks. The company offers flexible environments to businesses across different verticals, further providing personalised digital solutions at scale. VISIT WEBSITE Magnolia is a composable DXP that comes with no-code connector packs and low-code micro-frameworks for third-party integrations. It also offers an open-source version alongside its commercial plans enabling enterprises to build tailored use cases. VISIT WEBSITE Liferay DXP helps marketers deliver personalised and connected digital experiences across a broad range of channels, including customer portals, websites, intranets, mobile apps, and connected devices. It offers intuitive CMS, user analytics, and site management tools that businesses need to launch, test and optimise digital experiences for faster go-to-market. VISIT WEBSITE Powered by IBM Consulting, IBM iX offers a composable DXP, providing a comprehensive solution to make enterprises' systems future-ready. Utilising its data-driven insights and intelligent workflows, marketers can design and deliver human-centred experiences across the customer lifecycle. VISIT WEBSITE HCL Digital Experience (DX), forms part of a wider HCL Customer Experience (CX) product portfolio, offering core capabilities such as content management, DAM, CDP called Signals, and low-code application development. It provides services in government, life sciences, insurance, financial services, and other verticals. VISIT WEBSITE Contentstack is a headless CMS and Composable Digital Experience Platform (DXP) solution provider that helps marketers gain a competitive edge. It recently launched into Google Cloud Marketplace, and is also available on Microsoft Azure and AWS. It seamlessly enables mid-market brands to adopt its omnichannel campaign engine to drive higher conversions and sales. VISIT WEBSITE Bloomreach Commerce Experience Cloud provides businesses an edge with its modular capabilities: Content Management System (CMS), Discovery features for search and merchandising optimisation, and Engagement tools such as Customer Data Platforms (CDP) for personalisation and analytics. VISIT WEBSITE Adobe Experience Cloud offers a comprehensive set of services specifically designed to address the day-to-day requirements for personalised customer experience at scale. Its platform helps manage different digital content and assets to improve customer satisfaction. Some of its products include Adobe Gen Studio, Experience Manager Sites, Real-time CDP, and Marketo Engage. VISIT WEBSITE Acquia offers DXP solutions, comprising of two main elements: Acquia Drupal Cloud and Acquia Marketing Cloud. It can be accessed in both platform-as-a-service (PaaS) and software-as-a-service (SaaS) with additional components such as Site Factory for multisite management, digital asset management (DAM), CDP, personalisation, and Campaign Studio. VISIT WEBSITE
